NSE / BSEMaterials
β‚Ή426.85-1.50-0.35%
P/E18.9Mkt Capβ‚Ή3.60 K CrEV/EBITDA14.1

Aarti Drugs Limited

P/E18.9Mkt Capβ‚Ή3.60 K CrEV/EBITDA14.1
Company Profile

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Comfortable interest coverage of 8.2x

Concerns0

    Rule-based from financial data. Not advice.

    Price Historyβ–Ό 15.52% over 1Y

    Monthly Returns

    Unlock Monthly Returns

    Available on Pro and Institutional plans.

    Sign up free

    Year-to-Date ROI

    Unlock Year-to-Date ROI

    Available on Pro and Institutional plans.

    Sign up free

    Historical Volatility

    Unlock Historical Volatility

    Available on Pro and Institutional plans.

    Sign up free

    Historical Performance

    Revenue, profitability, and cash flow trends (β‚Ή Crores)

    Revenue (10Y)

    Operating Income (10Y)

    Net Profit (10Y)

    Operating Margin % (10Y)

    Dividend Payout % (10Y)

    Free Cash Flow (10Y)

    Growth Summary

    Latest fiscal year: Mar 2025

    Revenueβ‚Ή2.17 K Crβ–Ό 4.1%
    EBITDA Growthβ€”
    Net Profitβ‚Ή157.00 Crβ–² 10.6%
    Cash from Ops (CFO)β€”
    Free Cash Flow (FCF)β€”β–² 0.0%
    Revenue CAGR 5Y6.8%
    EBITDA CAGR 5Y1.2%
    Net Profit CAGR 5Y0.9%
    NP Growth 1Y10.6%

    Historical Growth

    Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

    YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
    Mar 2025β‚Ή2.17 K Crβ€”β‚Ή157.00 Crβ€”β€”12.5%-4.1%10.6%
    Mar 2024β‚Ή2.27 K Crβ€”β‚Ή142.00 Crβ€”β€”12.1%-9.2%-7.2%
    Mar 2023β‚Ή2.50 K Crβ€”β‚Ή153.00 Crβ€”β€”13.7%11.0%-21.5%
    Mar 2022β‚Ή2.25 K Crβ€”β‚Ή195.00 Crβ€”β€”20.0%17.5%-24.4%
    Mar 2021β‚Ή1.92 K Crβ€”β‚Ή258.00 Crβ€”β€”30.0%17.1%89.7%
    Mar 2020β‚Ή1.64 K Crβ€”β‚Ή136.00 Crβ€”β€”21.9%12.4%56.3%
    Mar 2019β‚Ή1.45 K Crβ€”β‚Ή87.00 Crβ€”β€”16.8%27.5%19.2%
    Mar 2018β‚Ή1.14 K Crβ€”β‚Ή73.00 Crβ€”β€”16.8%4.7%-2.7%
    Mar 2017β‚Ή1.09 K Crβ€”β‚Ή75.00 Crβ€”β€”19.4%1.2%13.6%
    Mar 2016β‚Ή1.08 K Crβ€”β‚Ή66.00 Crβ€”β€”18.9%-1.0%-15.4%

    Financial Statements

    Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

    Free plan Β· showing 1 year of data.Upgrade

    Consolidated Figures in USD Millions.

    Unnamed: 0TTM
    Revenue / Net Sales2,237
    Total Expenses1,949
    EBIT / Operating Profit288
    OPM %13%
    Other Income14
    Finance Costs28
    Depreciation & Amortisation50
    Profit Before Tax224
    Tax %-
    Net Profit / PAT190
    EPS (β‚Ή)20.87
    Dividend Payout %-

    Peer Comparison

    Materials sector peers, ranked by market cap

    CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
    Aarti Drugs Limitedthis co.β‚Ή3.60 K Crβ‚Ή2.17 K Cr18.902.6814.06-4.1%
    UltraTech Cement Ltdβ‚Ή3.55 L Crβ‚Ή71.89 K Cr48.605.0227.234.7%
    JSW Steel Limitedβ‚Ή2.88 L Crβ‚Ή1.28 L Cr38.003.4514.23-5.5%
    Asian Paints Ltd.β‚Ή2.77 L Crβ‚Ή29.55 K Cr69.6014.5035.04-5.4%
    Hindustan Zinc Ltd.β‚Ή2.66 L Crβ‚Ή33.97 K Cr25.5019.5718.5817.4%
    Coal India Limitedβ‚Ή2.64 L Crβ‚Ή1.59 K Cr12.4013.2416.335.1%
    Vedanta Limitedβ‚Ή2.49 L Crβ‚Ή74.30 K Cr26.503.3712.825.0%
    Industry Averageβ€”β‚Ή10.75 K Cr47.545.2330.19121.8%

    Learn while you research

    Hand-picked academy chapters to deepen your understanding of Aarti Drugs Limited and the metrics that matter.

    Browse the full Equiscale Academy